

Scaling Patient Insight: Agile, Portfolio-Level Approaches in R&D

Emily Goldsher-Diamond | Emily Wotczak | April Lewis

ZS Associates

Medtronic

PatientPartner

Today's Speakers



Emily Wotczak

Senior Business Process
Improvement Program
Manager

Medtronic



Emily Goldsher-Diamond

Site & Patient Engagement

ZS Associates



April Lewis

Clinical Solutions Lead

Patient Partner



Where Patient & Site Insights Fall Short

The Needs Defined by Industry



Engaging More Lay Patients and Different Sites



Raise Representation of Patients Engaged



Improve Speed and Access to Insights



Connect Insights to Actions that Drive Outcomes



Create a Scalable and Re-usable Solution


Sponsors shared they want broad and deep patient and site insight data “on-demand”...

across diseases, demographics and geographies...

and integrated more formally into the decision-making process from trial design to delivery

Future State: Scaled Patient & Site Voice


Modular capabilities powered by a shared intelligence engine...



Centralized AI Insights Engine – Powered by Patient Experience Bank

Unified data | Cross-voice learning and mining | Trends | Measurement

Streamlined Processes and Operating Norms



26,000+ Patients
(and growing!)

**Self-Reported Answers to 170
Standard Questions**

**180+ Indications &
Sub-Indications**

15+ Countries
(and growing!)

**Demographics (inclusive
of DEI and SDoH)**

The **ZS Patient Experience Bank** is the industry's first SAAS product providing structured, standardized and centralized patient survey data at scale

Data Categories

Care Delivery Preferences: Respondent perceptions, tolerance and preferences for when, how and where care is delivered.

Clinical Trial Perception: Awareness, comprehension, perception, and belief about clinical trial participation.

Digital Aptitude and Access: Respondent preferences and tolerance for use of technology in healthcare communications and care delivery.

Disability: Respondent experience with, and insight into, the impact of disabilities on healthcare experiences.

Disease Experience: Physical, psychological, and social impacts of respondent's medical conditions on daily life, and perceptions of their ability to manage and access adequate care.

Information & Communication: Respondent preferences for when, how, where, and from whom healthcare information related to disease management is gathered and discussed.

SDOH & Lifestyle Profile: Environmental and behavioral factors that impact respondent's well-being and health outcomes.

Combining data, analysis, and reporting, the Patient Experience Bank **complements other behavioral data sets (e.g., claims, EMR) by filling a gap with attitudinal data**

Use cases for PXB span across design through execution and above-trial strategy

PXB IN ACTION



Trial Design & Feasibility

- Disease and treatment burden
- Overall protocol optimization
- Eligibility criteria refinement
- Schedule of assessment enhancement
- Informed consent form simplification
- Decentralization and digital health opportunity identification
- Site and investigator selection
- Patient trial journey mapping

Piping key PB metrics into the data-driven study design application to make patient voice native to the design process



Patient Recruitment & Retention

- Recruitment strategy development
- Patient and site communication development
- Patient retention and support strategy
- Diversity and SDOH barrier identification and solution development

Identified an untapped channel and messaging for MDD clinical trial recruitment



Foundational and Regulatory Insights

- Asset and disease area strategy
- Early evidence and evidence generation strategy
- Unmet needs and opportunity identification
- Regional strategy
- Patient Experience Data for regulators
- Diversity Action Plan (DAP) development
- HRA and EMA submissions

30+ standardized disease-level patient overview dossiers provided to early development and asset leads.



What does it take to move from one-off patient engagement to a scalable, portfolio-level approach to patient insights?



How can organizations practically scale patient insights—across more countries, populations, and studies—without losing rigor?



How do you ensure patient insights actually drive decisions—and what are the most important first steps to scale impact in the next 12–18 months?

